Intrarosa for Vulvovaginal atrophy
Quick answer: Intrarosa is used for Vulvovaginal atrophy as part of a vaginal steroid (dhea/prasterone) treatment regimen. Intravaginal prasterone (DHEA) converted locally to estrogens and androgens to restore vaginal tissue The specific dosing for Vulvovaginal atrophy is determined by your prescriber based on individual factors.
Why is Intrarosa used for Vulvovaginal atrophy?
Intrarosa belongs to the Vaginal steroid (DHEA/prasterone) class. Intravaginal prasterone (DHEA) converted locally to estrogens and androgens to restore vaginal tissue This action makes it useful for treating or managing Vulvovaginal atrophy in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Intrarosa is the right choice for a specific patient depends on the type and severity of Vulvovaginal atrophy, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Vulvovaginal atrophy
Common adult dosing range: 6.5 mg vaginal insert once daily at bedtime. The actual dose for Vulvovaginal atrophy depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Intrarosa medicine page.
What to expect
Intrarosa treatment for Vulvovaginal atrophy typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Vulvovaginal atrophy
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Intrarosa is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Vaginal steroid (DHEA/prasterone) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Intrarosa
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Intrarosa full prescribing information · All Vaginal steroid (DHEA/prasterone) alternatives
Frequently asked questions
How effective is Intrarosa for Vulvovaginal atrophy?
Effectiveness varies by individual response, dose, and severity. Intrarosa is one of several treatment options for Vulvovaginal atrophy, supported by clinical evidence within the vaginal steroid (dhea/prasterone) class. Discuss expected response with your prescriber.
How long do I need to take Intrarosa for Vulvovaginal atrophy?
Treatment duration depends on the nature of Vulvovaginal atrophy — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Intrarosa when used for Vulvovaginal atrophy?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Intrarosa for Vulvovaginal atrophy?
Yes. Multiple medicines and non-drug options exist for Vulvovaginal atrophy. Alternatives within the vaginal steroid (dhea/prasterone) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.